Short-Term Biological Toxicity Prediction of [¹⁷⁷Lu]Lutetium-Oxodotreotide: An Original Retrospective Analysis.

ABSTRACT: Introduction: [¹⁷⁷Lu]Lutetium (Lu)-oxodotreotide is a radiopharmaceutical drug used as peptide receptor radionuclide therapy (PRRT) for somatostatin receptor-expressing neuroendocrine neoplasms. It provides an additional effective alternative treatment for these rare cancers. Although well tolerated, its safety profile must continue to be characterized to support its use as a first-line treatment or for additional cycles. This study evaluated factors associated with the occurrence of [¹⁷⁷Lu]Lu-oxodotreotide induced short-term toxicity. Materials and Methods: A retrospective observational monocentric study was carried out from July 2013 to October 2021. Inclusion criteria were defined as follows: patients who received at least four cy

SUBMITTER: Dubois J 

PROVIDER: S-EPMC11304756 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature